<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02220985</url>
  </required_header>
  <id_info>
    <org_study_id>2684.00</org_study_id>
    <secondary_id>NCI-2014-01301</secondary_id>
    <secondary_id>2684.00</secondary_id>
    <secondary_id>K23CA154532</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>R01HL121568</secondary_id>
    <nct_id>NCT02220985</nct_id>
  </id_info>
  <brief_title>Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD</brief_title>
  <official_title>A Phase II Study Evaluating Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well selective T cell depletion works in preventing
      graft-versus-host disease (GVHD) in patients with acute lymphocytic leukemia, acute myeloid
      leukemia, or chronic myelogenous leukemia undergoing donor peripheral blood stem cell
      transplant. Giving chemotherapy and total-body irradiation before a donor peripheral blood
      stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's
      immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor
      are infused into the patient they may help the patient's bone marrow make stem cells, red
      blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor
      can make an immune response against the body's normal cells. Removing a subset of the T cells
      from the donor cells before transplant may stop this from happening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To estimate the probability of developing chronic GHVD among patients who receive naive T
      cell (TN)-depleted peripheral blood stem cell transplant (PBSCT) in each of the following
      groups: a) Arm A: patients who receive TN-depleted peripheral blood stem cells (PBSC) from a
      human leukocyte antigens (HLA) matched related donor (MRD) following high-intensity
      myeloablative conditioning (total body irradiation [TBI] 1320 cGy, thiotepa, fludarabine
      phosphate [fludarabine]) and pharmacological immunosuppression with tacrolimus and
      methotrexate; b) Arm B: patients who receive TN-depleted PBSC from a MRD following
      lower-intensity myeloablative conditioning (TBI 400 cGy, thiotepa, fludarabine and
      cyclophosphamide) and pharmacological immunosuppression with tacrolimus and mycophenolate
      mofetil (MMF); c) Arm C: patients who receive TN-depleted PBSC from a HLA-matched unrelated
      donor (MUD) following high-intensity myeloablative conditioning (TBI 1320 cGy, thiotepa,
      fludarabine) and pharmacological immunosuppression with tacrolimus and methotrexate; d) Arm
      D: patients who receive TN-depleted PBSC from a MUD following lower-intensity myeloablative
      conditioning (TBI 400 cGy, thiotepa, fludarabine and cyclophosphamide) and pharmacological
      immunosuppression with tacrolimus and MMF.

      II. To estimate the probability of acute (a)GVHD grade II-IV following TN-depleted (TND)
      PBSCT with tacrolimus and methotrexate (Arm A) or MMF (Arm B) GVHD prophylaxis in MRD
      recipients.

      III. Estimate the rate of aGVHD grade II-IV following TND PBSCT with tacrolimus and
      methotrexate (Arm C) or MMF (Arm D) prophylaxis in recipients of MUD hematopoietic cell
      transplantation (HCT).

      IV. Estimate the probability of graft failure in recipients of CD45RA+ TN-depleted PBSCT with
      tacrolimus and methotrexate (MTX) or MMF GVHD prophylaxis.

      SECONDARY OBJECTIVES:

      I. Estimate the probability of transplant-related mortality by day 100.

      II. Estimate the probability of relapse.

      III. Evaluate immune reconstitution and pathogen-specific immune reconstitution.

      OUTLINE: Patients are assigned to 1 of 4 treatment arms.

      CONDITIONING:

      ARMS A AND C (high-intensity myeloablative conditioning): Patients undergo total body
      irradiation twice daily (BID) on days -10 to -7. Patients also receive thiotepa intravenously
      (IV) over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6
      to -2.

      ARMS B AND D (lower-intensity myeloablative conditioning): Patients receive cyclophosphamide
      IV over 1 hour on day -6, fludarabine phosphate IV over 30 minutes on days -6 to -2, and
      thiotepa IV over 4 hours on days -5 and -4. Patients also undergo total body irradiation once
      daily (QD) on days -2 and -1.

      TRANSPLANT: In all arms, patients undergo allogeneic HSCT with granulocyte colony-stimulating
      factor (GCSF)-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.

      GVHD PROPHYLAXIS:

      ARMS A AND C: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or orally
      (PO) (BID if given PO) for 50 days with taper in the absence of GVHD. Patients also receive
      methotrexate IV on days 1, 3, 6, and 11.

      ARMS B AND D: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if
      given PO) for 50 days and mycophenolate mofetil IV and PO every 8 hours on days -3 to
      approximately day 30, with or without taper at the discretion of the treating physician.
      Mycophenolate mofetil should be continued or resumed after day 30 if donor chimerism is low,
      after discussion with the principal investigator.

      After completion of study treatment, patients are followed up at 80-100 days, 360 days, and
      then yearly for up to 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2015</start_date>
  <primary_completion_date type="Anticipated">February 3, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft failure</measure>
    <time_frame>Up to day 28</time_frame>
    <description>Defined operationally as failure to reach an absolute neutrophil count (ANC) of &gt; 500/ul for 3 consecutive days by day 28 or irreversible decrease in ANC to &lt; 100 after an established donor graft.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of chronic graft-versus-host disease (GHVD), defined operationally as the occurrence of compatible symptoms meeting National Institutes of Health criteria and requiring systemic pharmacological immunosuppression</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Match related donor (MRD)-high intensity (Arm A), MRD-lower intensity (Arm B), match unrelated donor (MUD)-high intensity (Arm C) and MUD-lower intensity (Arm D) cohorts will be analyzed separately.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of acute graft-versus-host disease (GVHD) grades II-IV</measure>
    <time_frame>Up to day 100</time_frame>
    <description>Defined operationally as the occurrence of compatible symptoms or signs in the skin, gastrointestinal tract, or liver.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Requirement for secondary systemic therapy for acute graft-versus-host disease (GVHD) management</measure>
    <time_frame>Up to day 100</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Requirement of immunosuppression after transplant</measure>
    <time_frame>At 2 years after transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to completion of all immunosuppression</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to completion of prednisone</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Use of additional immune suppressive agents other than first line therapy (prednisone and tacrolimus/cyclosporine)</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chimerism analysis</measure>
    <time_frame>Up to 360 days</time_frame>
    <description>Will be analyzed from peripheral blood or marrow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Defined by the presence of malignant cells in marrow, peripheral blood, or extramedullary sites by histopathology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to absolute neutrophil count (ANC) of &gt; 1,000/uL on the first of three consecutive test results</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to absolute neutrophil count (ANC) of &gt; 500/uL on the first of three consecutive days</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet count &gt; 20,000/uL for 3 days without transfusion</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet count &gt; 50,000/uL for 3 days without transfusion</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant related mortality</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Defined as mortality in any patient for whom there has not been a diagnosis of relapse.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Acute Biphenotypic Leukemia</condition>
  <condition>Acute Leukemia of Ambiguous Lineage</condition>
  <condition>Acute Undifferentiated Leukemia</condition>
  <condition>Adult Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia in Remission</condition>
  <condition>Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Blastic Plasmacytoid Dendritic Cell Neoplasm</condition>
  <condition>Childhood Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Childhood Acute Myeloid Leukemia in Remission</condition>
  <condition>Lymphoblastic Lymphoma</condition>
  <condition>Myelodysplastic Syndrome With Excess Blasts</condition>
  <condition>Myelodysplastic Syndrome With Excess Blasts-1</condition>
  <condition>Myelodysplastic Syndrome With Excess Blasts-2</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Recurrent Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Childhood Acute Myeloid Leukemia</condition>
  <condition>Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Refractory Acute Lymphoblastic Leukemia</condition>
  <condition>Refractory Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm A (MRD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIGH-INTENSITY MYELOABLATIVE CONDITIONING: Patients undergo total body irradiation BID on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2.
TRANSPLANT: In all arms, patients undergo allogeneic HSCT with GCSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.
GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days with taper in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (MRD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LOWER-INTENSITY MYELOABLATIVE CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on day -6, fludarabine phosphate IV over 30 minutes on days -6 to -2, and thiotepa IV over 4 hours on days -5 and -4. Patients also undergo total body irradiation QD on days -2 and -1.
TRANSPLANT: In all arms, patients undergo allogeneic HSCT with GCSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.
GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days and mycophenolate mofetil IV and PO every 8 hours on day -3 to approximately day 30, with or without taper at the discretion of the treating physician. Mycophenolate mofetil should be continued or resumed after day 30 if donor chimerism is low, after discussion with the Principal Investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (MUD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIGH-INTENSITY MYELOABLATIVE CONDITIONING: Patients undergo total body irradiation BID on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2.
TRANSPLANT: In all arms, patients undergo allogeneic HSCT with G-CSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.
GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days with taper in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D (MUD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LOWER-INTENSITY MYELOABLATIVE CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on day -6, fludarabine phosphate IV over 30 minutes on days -6 to -2, and thiotepa IV over 4 hours on days -5 and -4. Patients also undergo total body irradiation QD on days -2 and -1.
TRANSPLANT: In all arms, patients undergo allogeneic HSCT with G-CSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.
GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days and mycophenolate mofetil IV and PO every 8 hours on day -3 to approximately day 30, with or without taper at the discretion of the treating physician. Mycophenolate mofetil should be continued or resumed after day 30 if donor chimerism is low, after discussion with the Principal Investigator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic HSCT</description>
    <arm_group_label>Arm A (MRD)</arm_group_label>
    <arm_group_label>Arm B (MRD)</arm_group_label>
    <arm_group_label>Arm C (MUD)</arm_group_label>
    <arm_group_label>Arm D (MUD)</arm_group_label>
    <other_name>Allogeneic Hematopoietic Cell Transplantation</other_name>
    <other_name>allogeneic stem cell transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (MRD)</arm_group_label>
    <arm_group_label>Arm B (MRD)</arm_group_label>
    <arm_group_label>Arm C (MUD)</arm_group_label>
    <arm_group_label>Arm D (MUD)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (MRD)</arm_group_label>
    <arm_group_label>Arm B (MRD)</arm_group_label>
    <arm_group_label>Arm C (MUD)</arm_group_label>
    <arm_group_label>Arm D (MUD)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm A (MRD)</arm_group_label>
    <arm_group_label>Arm B (MRD)</arm_group_label>
    <arm_group_label>Arm C (MUD)</arm_group_label>
    <arm_group_label>Arm D (MUD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (MRD)</arm_group_label>
    <arm_group_label>Arm C (MUD)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given IV and PO</description>
    <arm_group_label>Arm B (MRD)</arm_group_label>
    <arm_group_label>Arm D (MUD)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo PBSCT with GCSF-mobilized CD34-enriched PBSC</description>
    <arm_group_label>Arm A (MRD)</arm_group_label>
    <arm_group_label>Arm B (MRD)</arm_group_label>
    <arm_group_label>Arm C (MUD)</arm_group_label>
    <arm_group_label>Arm D (MUD)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSCT</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>peripheral stem cell support</other_name>
    <other_name>Peripheral Stem Cell Transplant</other_name>
    <other_name>peripheral stem cell transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo PBSCT with CD45RA-depleted cells</description>
    <arm_group_label>Arm A (MRD)</arm_group_label>
    <arm_group_label>Arm B (MRD)</arm_group_label>
    <arm_group_label>Arm C (MUD)</arm_group_label>
    <arm_group_label>Arm D (MUD)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSCT</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>peripheral stem cell support</other_name>
    <other_name>Peripheral Stem Cell Transplant</other_name>
    <other_name>peripheral stem cell transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Arm A (MRD)</arm_group_label>
    <arm_group_label>Arm B (MRD)</arm_group_label>
    <arm_group_label>Arm C (MUD)</arm_group_label>
    <arm_group_label>Arm D (MUD)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (MRD)</arm_group_label>
    <arm_group_label>Arm B (MRD)</arm_group_label>
    <arm_group_label>Arm C (MUD)</arm_group_label>
    <arm_group_label>Arm D (MUD)</arm_group_label>
    <other_name>1,1',1''-Phosphinothioylidynetrisaziridine</other_name>
    <other_name>Girostan</other_name>
    <other_name>N,N', N''-Triethylenethiophosphoramide</other_name>
    <other_name>Oncotiotepa</other_name>
    <other_name>STEPA</other_name>
    <other_name>Tepadina</other_name>
    <other_name>TESPA</other_name>
    <other_name>Tespamin</other_name>
    <other_name>Tespamine</other_name>
    <other_name>Thio-Tepa</other_name>
    <other_name>Thiofosfamide</other_name>
    <other_name>Thiofozil</other_name>
    <other_name>Thiophosphamide</other_name>
    <other_name>Thiophosphoramide</other_name>
    <other_name>Thiotef</other_name>
    <other_name>Tifosyl</other_name>
    <other_name>TIO TEF</other_name>
    <other_name>Tio-tef</other_name>
    <other_name>Triethylene thiophosphoramide</other_name>
    <other_name>triethylenethiophosphoramide</other_name>
    <other_name>Tris(1-aziridinyl)phosphine sulfide</other_name>
    <other_name>TSPA</other_name>
    <other_name>WR 45312</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Arm A (MRD)</arm_group_label>
    <arm_group_label>Arm B (MRD)</arm_group_label>
    <arm_group_label>Arm C (MUD)</arm_group_label>
    <other_name>TOTAL BODY IRRADIATION</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are considered appropriate candidates for allogeneic hematopoietic stem
             cell transplantation and have one of the following diagnoses:

               -  Acute lymphocytic leukemia in first or subsequent remission

               -  Acute myeloid leukemia in first or subsequent remission

               -  Acute lymphocytic leukemia in relapse or primary refractory disease with a
                  circulating blast count of no more than 10,000/mm^3 (Arms A or C only)

               -  Acute myeloid leukemia in relapse or primary refractory disease with a
                  circulating blast count of no more than 10,000/mm^3 (Arms A or C only)

               -  Refractory anemia with excess blasts (RAEB-1 and RAEB-2) (if the patient has
                  received previous induction chemotherapy within 60 days)

               -  Chronic myelogenous leukemia with a history of accelerated phase or blast crisis
                  (if the patient has received at least one course of induction chemotherapy)

               -  Other acute leukemia or related neoplasm (including but not limited to
                  'biphenotypic', 'undifferentiated' or 'ambiguous lineage' acute leukemia, blastic
                  plasmacytoid dendritic cell neoplasm or lymphoblastic lymphoma)

          -  Patients 0-49 years old will be enrolled in Arm A or C (high-intensity)

          -  Patients 50-60 years old will be enrolled in Arm B or D (lower intensity); patients
             eligible for Arms B or D also include those who have received previous allogeneic HCT,
             or who have co-morbid conditions rendering them unsuitable for high-dose conditioning,
             determined in consultation with the principal investigator

          -  Patient with a HLA-matched (HLA-A, B, C, and DR beta 1 [DRB1] molecularly matched)
             unrelated donor or related donor capable of donating PBSC

        DONOR INCLUSION:

          -  HLA-matched related donors &gt;= 18 years and capable and willing to donate PBSC (Arms A
             and B)

          -  HLA-matched unrelated donors (HLA-A, B, C, and DRB1 matched based on high-resolution
             typing) capable and willing to donate PBSC (Arms C and D)

        Exclusion Criteria:

          -  Patients with central nervous system (CNS) involvement refractory to intrathecal
             chemotherapy and/or standard cranial-spinal radiation

          -  Patients on other experimental protocols for prevention of acute GVHD

          -  Patient weight &gt;= 100 kg; patients &gt;= 70 kg with MUDs must be discussed with the
             principal investigator

          -  Patients who are human immunodeficiency virus positive (HIV+)

          -  Patients with uncontrolled infections for whom myeloablative HCT is considered
             contraindicated by the consulting infectious disease physician (upper respiratory
             tract viral infection does not constitute an uncontrolled infection in this context)

          -  Patients with organ dysfunction

        ARM A OR C EXCLUSION:

          -  Creatinine &gt; 1.5 mg/dl at the present time; patients with a known history of
             creatinine &gt; 1.5 mg/dl must have a current estimated creatinine clearance of &gt; 40
             ml/min

          -  Cardiac ejection fraction &lt; 45%

          -  Diffusing capacity of the lung for carbon monoxide (DLCO) corrected &lt; 60%

          -  Liver function abnormality; patients who have liver function tests (LFTs) (including
             total bilirubin, aspartate aminotransferase [AST] and alanine aminotransferase [ALT])
             &gt;= twice the upper limit of normal should be evaluated by a gastrointestinal (GI)
             physician; unless there is a clear precipitating factor (such as an azole,
             methotrexate, Bactrim or another drug); if the GI physician considers that HCT on the
             high-intensity arms of protocol is contraindicated for that patient the patient may be
             considered for treatment on the lower intensity arm of the protocol or excluded from
             the protocol; patients with Gilbert's syndrome and no other known liver function
             abnormality and patients with reversible drug-related transaminitis do not necessarily
             require GI consultation and may be included on the high-intensity arms of the protocol

        ARM B OR D EXCLUSION:

          -  Creatinine &gt; 2.0 mg/dl at the present time; patients with a known history of
             creatinine &gt; 1.5 mg/dl must have a current estimated creatinine clearance &gt; 40 ml/min

          -  Cardiac ejection fraction &lt; 35%

          -  DLCO corrected &lt; 50%; patients with a DLCO 50-60% must also have a partial pressure of
             oxygen (pO2) of &gt; 80 mmHg

          -  Liver function abnormality; patients who have LFTs &gt;= twice the upper limit of normal
             should be evaluated by a GI physician unless there is a clear precipitating factor
             (such as an azole, methotrexate, Bactrim or another drug); patients with fulminant
             liver failure, cirrhosis with evidence of portal hypertension or bridging fibrosis,
             alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices,
             hepatic encephalopathy, or correctable hepatic synthetic dysfunction evidenced by
             prolongation of the prothrombin time, ascites related to portal hypertension,
             bacterial or fungal abscess, biliary obstruction, chronic viral hepatitis with total
             serum bilirubin &gt; 3 mg/dL, and symptomatic biliary disease will be excluded

          -  Patients will be excluded from Arms A and C if they have received a previous
             myeloablative transplant; patients who have received a prior HCT at least 6 months
             prior may be considered for inclusion on Arms B or D after discussion with the
             principal investigator (PI)

          -  Patients with a life expectancy &lt; 3 months from co-existing disease other than the
             leukemia or RAEB

          -  Patients who are pregnant or breast-feeding

          -  Fertile patients of child bearing age unwilling to use contraception during and for 12
             months post-transplant

          -  Patients with a significant other medical conditions that would make them unsuitable
             for transplant

          -  Patients with a known hypersensitivity to tacrolimus, methotrexate (Arm A or C) or MMF
             (Arm B or D)

        DONOR EXCLUSION:

          -  Donors who are HIV-1, HIV-2, human T-lymphotropic virus (HTLV)-1, HTLV-2 seropositive
             or with active hepatitis B or hepatitis C virus infection

          -  Donors who fail eligibility requirements for donation of cells or tissue for donation
             of a Human Cell and Tissue Products (HCT/P) will be excluded unless use of the cells
             complies urgent medical need or allogeneic use in a first-degree or second-degree
             relative

          -  Unrelated donors donating outside of the United States of America (USA)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Bleakley</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute (UPCI)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Warren D. Shlomchik</last_name>
      <phone>412-624-5322</phone>
      <email>warrens@pitt.edu</email>
    </contact>
    <investigator>
      <last_name>Warren D. Shlomchik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Bleakley</last_name>
      <phone>206-667-6572</phone>
      <email>mbleakle@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Marie Bleakley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2014</study_first_submitted>
  <study_first_submitted_qc>August 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2014</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Accelerated Phase</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
    <mesh_term>Anemia, Refractory, with Excess of Blasts</mesh_term>
    <mesh_term>Leukemia, Biphenotypic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

